Core Points - Hong Kong Stock Exchange has officially canceled the listing status of four companies, including Nohow Health, marking a significant event in the biotech sector since Nohow Health was the first biotech firm to be forcibly delisted since the introduction of the 18A biotech board in 2018 [1] - Nohow Health failed to meet the resumption guidelines by September 27, 2025, leading to its delisting on October 27, 2025, with shares no longer available for public trading [1] - The company has appointed three joint provisional liquidators to manage its assets and affairs, and a court hearing for a winding-up order is scheduled for November 14, 2025 [1] Company Overview - Nohow Health, established in 2015, focused on early screening for high-incidence cancers, with core business areas including the development and commercialization of screening products for colorectal, gastric, and cervical cancers [2] - The company launched three core products, with Changweiqing being the only colorectal cancer screening product approved by the National Medical Products Administration in China, highlighting its industry rarity [2] - Nohow Health went public on the Hong Kong Stock Exchange in February 2021, achieving an oversubscription of approximately 4,133 times and raising over 850 billion HKD, setting a record for the second-largest oversubscription in Hong Kong history [2] Recent Developments - In August 2023, Nohow Health faced allegations of financial fraud, leading to a temporary suspension of trading in March 2024 and a delay in the publication of its 2023 annual report [2] - The company has not disclosed its financial performance for 2023 and 2024, and during the suspension period, there were changes in the management team, including the resignation of co-founder Zhu Yeqing as chairman and CEO due to health reasons [2] - The other three companies delisted alongside Nohow Health—Pujiang International, Jianzhong Construction, and Shangkun Real Estate—had also been suspended for extended periods and failed to meet the resumption guidelines set by the Hong Kong Stock Exchange [3]
4家公司集体挥别港股市场，诺辉健康成首家被强制退市的18A企业